Drugs targeting wild-type p53 serve to enhance the stabilization of p53 via several mechanisms: 1) Nutlin 3a, benzodiazepinediones, and spiro-oxindoles target the p53-Mdm2 interaction to reduce Mdm2-mediated proteasomal degradation; 2) RITA (Reactivation of p53 and induction of tumor cell apoptosis) directly binds to p53, inducing a conformational change that inhibits Mdm2 binding; and 3) Mdmx inhibitors, which block Mdmx-Mdm2 dimerization to activate p53 [40]. The gene discussed is MDM2; the disease is neoplasm.